Ellen J. Hoffman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ellen J. Hoffman has a total of 378 co-authors. Here are the top co-authors by number of shared publications:
- April Pruitt
Interdepartmental Neuroscience Program, Yale School of Medicine, New Haven, USA
5 shared publications Suha Khan
5 shared publicationsCatalina Sakai
Child Study Center, Yale School of Medicine, New Haven, CT 06510, USA
4 shared publications- Kristen J. Brennand
Yale University
4 shared publications Matthew State
4 shared publications- Sarah E. Fitzpatrick
Interdepartmental Neuroscience Program, Yale School of Medicine, New Haven, USA
4 shared publications
Latest Publications
- 10 October 2026
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 65 (10) , S385-S386
From Bench to Bedside: Advancing our Understanding of Autism Risk Gene Function to Develop New Treatments
- 10 October 2026
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 65 (10) , S385-S386
From Bench to Bedside: Advancing our Understanding of Autism Risk Gene Function to Develop New Treatments
- Open Access
- 15 September 2026
- Published by Elsevier in Biological Psychiatry
Leveraging Scalable Nonmammalian Systems for Large-Scale Studies of Autism Risk Gene Function
- 15 September 2026
- Published by Elsevier in Biological Psychiatry
Open AccessLeveraging Scalable Nonmammalian Systems for Large-Scale Studies of Autism Risk Gene Function
- 30 July 2026
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 46 (35)
Brain-Wide Circuitry Underlying Altered Auditory Habituation in Zebrafish Models of Autism
Auditory processing is widely understood to occur differently in autism, though the patterns of brain activity underlying these differences are not well understood. The diversity of autism also means brain-wide networks may change in various ways to produce similar behavioral outputs. We used larval zebrafish to investigate auditory habituation in three genetic lines relevant to autism: fmr1 , mecp2 , and cntnap2 . In free-swimming behavioral tests, we found each line had a unique profile of auditory hyperresponsiveness and/or reduced habituation compared with wild types. Combining the optical transparency of larval zebrafish with genetically encoded calcium indicators and light-sheet microscopy, we then observed brain-wide activity at cellular resolution during repeated sound stimuli. Each line showed unique alterations in brain-wide spontaneous activity, auditory processing, and adaptation in response to repetitive acoustic stimuli. We also observed commonalities in activity across our genetic lines that indicate shared circuit changes underlying certain aspects of their behavioral phenotypes. These were predominantly in regions involved in sensory integration and sensorimotor gating rather than primary auditory areas. Overlapping phenotypes include differences in the activity and functional connectivity of the telencephalon, dopaminergic regions, and the locus ceruleus. Unique phenotypes include increased activity in auditory regions and excitatory/inhibitory imbalance in the cerebellum in fmr1 and differences in network activity over time in mecp2 and cntnap2 . Comparing these distinct but overlapping brain-wide auditory networks suggests that diverse genetic factors may contribute to similar behavioral effects through a range of circuit- and network-scale mechanisms.
- 30 July 2026
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 46 (35)
Brain-Wide Circuitry Underlying Altered Auditory Habituation in Zebrafish Models of Autism
Auditory processing is widely understood to occur differently in autism, though the patterns of brain activity underlying these differences are not well understood. The diversity of autism also means brain-wide networks may change in various ways to produce similar behavioral outputs. We used larval zebrafish to investigate auditory habituation in three genetic lines relevant to autism: fmr1 , mecp2 , and cntnap2 . In free-swimming behavioral tests, we found each line had a unique profile of auditory hyperresponsiveness and/or reduced habituation compared with wild types. Combining the optical transparency of larval zebrafish with genetically encoded calcium indicators and light-sheet microscopy, we then observed brain-wide activity at cellular resolution during repeated sound stimuli. Each line showed unique alterations in brain-wide spontaneous activity, auditory processing, and adaptation in response to repetitive acoustic stimuli. We also observed commonalities in activity across our genetic lines that indicate shared circuit changes underlying certain aspects of their behavioral phenotypes. These were predominantly in regions involved in sensory integration and sensorimotor gating rather than primary auditory areas. Overlapping phenotypes include differences in the activity and functional connectivity of the telencephalon, dopaminergic regions, and the locus ceruleus. Unique phenotypes include increased activity in auditory regions and excitatory/inhibitory imbalance in the cerebellum in fmr1 and differences in network activity over time in mecp2 and cntnap2 . Comparing these distinct but overlapping brain-wide auditory networks suggests that diverse genetic factors may contribute to similar behavioral effects through a range of circuit- and network-scale mechanisms.
- Top Cited PapersOpen Access
- 24 April 2026
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (5) , 1079-1094
Transcriptomic and phenotypic convergence of neurodevelopmental disorder risk genes in vitro and in vivo
Diverse risk genes have been identified for neurodevelopmental disorders (NDDs), but how these genes converge on similar biological pathways in neurons, and thus give rise to similar phenotypes, is unclear. Here we apply a pooled CRISPR approach to successfully target 23 NDD loss-of-function genes with roles in chromatin biology and examine convergent effects on gene expression across human induced pluripotent stem cell-derived neural progenitor cells, glutamatergic neurons and GABAergic neurons. Points of convergence vary between these cell types, with the greatest number of convergent genes and strongest convergent networks in mature glutamatergic neurons, where they broadly represent synaptic, epigenetic and, unexpectedly, mitochondrial pathways. The most convergent networks were observed between NDD genes with shared biological annotations, clinical associations and co-expression patterns in human post-mortem brain. Drugs that were predicted to reverse convergent transcriptomic signatures and/or arousal and sensory processing behaviors ameliorated behavioral phenotypes in zebrafish NDD gene mutants. These results suggest that convergent effects of NDD risk genes could provide clinically useful insights.
- 24 April 2026
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (5) , 1079-1094
Top Cited PapersOpen AccessTranscriptomic and phenotypic convergence of neurodevelopmental disorder risk genes in vitro and in vivo
Diverse risk genes have been identified for neurodevelopmental disorders (NDDs), but how these genes converge on similar biological pathways in neurons, and thus give rise to similar phenotypes, is unclear. Here we apply a pooled CRISPR approach to successfully target 23 NDD loss-of-function genes with roles in chromatin biology and examine convergent effects on gene expression across human induced pluripotent stem cell-derived neural progenitor cells, glutamatergic neurons and GABAergic neurons. Points of convergence vary between these cell types, with the greatest number of convergent genes and strongest convergent networks in mature glutamatergic neurons, where they broadly represent synaptic, epigenetic and, unexpectedly, mitochondrial pathways. The most convergent networks were observed between NDD genes with shared biological annotations, clinical associations and co-expression patterns in human post-mortem brain. Drugs that were predicted to reverse convergent transcriptomic signatures and/or arousal and sensory processing behaviors ameliorated behavioral phenotypes in zebrafish NDD gene mutants. These results suggest that convergent effects of NDD risk genes could provide clinically useful insights.
- Open Access
Whole-brain cellular-resolution functional network properties of seizure susceptibility
Despite its prevalence and clinical impacts, epilepsy remains incompletely understood in terms of the population dynamics that mediate seizure susceptibility, initiation, and propagation across brain-wide networks. In this study, we have performed calcium imaging in zebrafish, brain-wide and at cellular resolution, at baseline and as seizures are induced using the GABA A receptor antagonist pentylenetetrazol (PTZ). We have then modeled the network architecture in wild-type and scn1lab −/− larvae, which are seizure-prone and serve as a model for Dravet syndrome. scn1lab −/− larvae show increased pair-wise correlations between neurons when exposed to PTZ, and graph analyses of these correlations revealed genotype-specific network alterations during seizures, identifying regions and metrics linked to seizure onset. Using generative network modeling, we then explored the wiring rules that govern activity in these networks, identifying specific network properties linked to seizure susceptibility that were only detectable using large-scale, cellular-resolution data. Even at baseline in the absence of seizures, these rules differed by genotype in a way that enabled the identification of scn1lab −/− larvae and predicted individuals’ seizure risk independently of their observable phenotype. These findings uncover the cellular-resolution network properties of a zebrafish model of Dravet syndrome and establish a predictive framework for seizure susceptibility grounded in multi-scale functional connectivity.
Open AccessWhole-brain cellular-resolution functional network properties of seizure susceptibility
Despite its prevalence and clinical impacts, epilepsy remains incompletely understood in terms of the population dynamics that mediate seizure susceptibility, initiation, and propagation across brain-wide networks. In this study, we have performed calcium imaging in zebrafish, brain-wide and at cellular resolution, at baseline and as seizures are induced using the GABA A receptor antagonist pentylenetetrazol (PTZ). We have then modeled the network architecture in wild-type and scn1lab −/− larvae, which are seizure-prone and serve as a model for Dravet syndrome. scn1lab −/− larvae show increased pair-wise correlations between neurons when exposed to PTZ, and graph analyses of these correlations revealed genotype-specific network alterations during seizures, identifying regions and metrics linked to seizure onset. Using generative network modeling, we then explored the wiring rules that govern activity in these networks, identifying specific network properties linked to seizure susceptibility that were only detectable using large-scale, cellular-resolution data. Even at baseline in the absence of seizures, these rules differed by genotype in a way that enabled the identification of scn1lab −/− larvae and predicted individuals’ seizure risk independently of their observable phenotype. These findings uncover the cellular-resolution network properties of a zebrafish model of Dravet syndrome and establish a predictive framework for seizure susceptibility grounded in multi-scale functional connectivity.
- Top Cited PapersOpen Access
- 16 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (12)
Pharmaco-behavioral profiling identifies suppressors of autism gene–associated phenotypes in zebrafish
Pharmaco-behavioral screens in scalable in vivo systems have critical advantages for drug discovery relevant to large-effect autism spectrum disorder (ASD) genes. Here, we establish a database and open-source website of the behavioral signatures of 520 US Food and Drug Administration (FDA)-approved drugs using high-throughput assays of basic sensory processing and arousal behaviors in larval zebrafish. By leveraging the behavioral profiles of 9 large-effect ASD gene mutants, we identify enrichment of pharmacological mechanisms that anticorrelate with subgroups of ASD genes with shared behavioral phenotypes. Screening of anticorrelating drugs in mutants of two ASD genes, SCN2A and DYRK1A , uncovers compounds that suppress mutant behavioral phenotypes. We identify estropipate, an estrogen receptor agonist, and paclitaxel, a microtubule inhibitor, as the top suppressors in scn1lab and dyrk1a mutants, respectively, and levocarnitine (LEVO), a mitochondrial modulator and carnitine supplement, as a top suppressor of both mutant behavioral phenotypes. Finally, we find that LEVO rescues regional brain activity deficits and dysregulated lipid metabolic pathways in mutants, as well as signaling deficits in human pluripotent stem cell–derived glutamatergic neurons carrying mutations in SCN2A and DYRK1A , demonstrating conservation of drug rescue across systems. Therefore, our study establishes a pharmaco-behavioral resource for precision medicine-based drug discovery, illuminating targets relevant to large-effect ASD genes.
- 16 March 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (12)
Top Cited PapersOpen AccessPharmaco-behavioral profiling identifies suppressors of autism gene–associated phenotypes in zebrafish
Pharmaco-behavioral screens in scalable in vivo systems have critical advantages for drug discovery relevant to large-effect autism spectrum disorder (ASD) genes. Here, we establish a database and open-source website of the behavioral signatures of 520 US Food and Drug Administration (FDA)-approved drugs using high-throughput assays of basic sensory processing and arousal behaviors in larval zebrafish. By leveraging the behavioral profiles of 9 large-effect ASD gene mutants, we identify enrichment of pharmacological mechanisms that anticorrelate with subgroups of ASD genes with shared behavioral phenotypes. Screening of anticorrelating drugs in mutants of two ASD genes, SCN2A and DYRK1A , uncovers compounds that suppress mutant behavioral phenotypes. We identify estropipate, an estrogen receptor agonist, and paclitaxel, a microtubule inhibitor, as the top suppressors in scn1lab and dyrk1a mutants, respectively, and levocarnitine (LEVO), a mitochondrial modulator and carnitine supplement, as a top suppressor of both mutant behavioral phenotypes. Finally, we find that LEVO rescues regional brain activity deficits and dysregulated lipid metabolic pathways in mutants, as well as signaling deficits in human pluripotent stem cell–derived glutamatergic neurons carrying mutations in SCN2A and DYRK1A , demonstrating conservation of drug rescue across systems. Therefore, our study establishes a pharmaco-behavioral resource for precision medicine-based drug discovery, illuminating targets relevant to large-effect ASD genes.
- Open Access
Estradiol modulates neuronal network hyperexcitability in select NDD risk genes
The biological basis for the male sex bias in autism spectrum disorder (ASD) is poorly understood. Differential exposure to sex hormones during neurodevelopment has been proposed as a potential modulator of risk. To test the hypothesis that early exposure to the principal biologically active estrogen, 17β-estradiol, confers a protective effect against mutations in ASD and neurodevelopmental disorder (NDD) genes, we conduct a dual-system multi-modal screen of 36 functionally diverse, large-effect ASD/NDD genes in human induced pluripotent stem cell and larval zebrafish models. We uncover estradiol-dependent effects across genes and modalities, revealing convergent and divergent gene-by-estradiol interactions at the transcriptomic, circuit, and behavioral levels. Estradiol broadly ameliorates ASD/NDD gene expression patterns across all knockouts examined and selectively dampens network hyperexcitability phenotypes in human neurons and zebrafish brains in a subset of ASD/NDD genes ( ASH1L , SCN2A, ANK2, CACNA1G, SHANK3) . Two genes, ASH1L and SCN2A , show comprehensive estradiol rescue of differential gene expression and network bursting activity in human neurons as well as sleep-wake and visual-startle phenotypes in larval zebrafish mutants. Moreover, estradiol rescues seizures and regional increases in brain activity in SCN2A larval zebrafish mutants. Altogether, we describe novel roles of estradiol in modulating network hyperexcitability in the context of loss of function mutations of select ASD/NDD genes.
Open AccessEstradiol modulates neuronal network hyperexcitability in select NDD risk genes
The biological basis for the male sex bias in autism spectrum disorder (ASD) is poorly understood. Differential exposure to sex hormones during neurodevelopment has been proposed as a potential modulator of risk. To test the hypothesis that early exposure to the principal biologically active estrogen, 17β-estradiol, confers a protective effect against mutations in ASD and neurodevelopmental disorder (NDD) genes, we conduct a dual-system multi-modal screen of 36 functionally diverse, large-effect ASD/NDD genes in human induced pluripotent stem cell and larval zebrafish models. We uncover estradiol-dependent effects across genes and modalities, revealing convergent and divergent gene-by-estradiol interactions at the transcriptomic, circuit, and behavioral levels. Estradiol broadly ameliorates ASD/NDD gene expression patterns across all knockouts examined and selectively dampens network hyperexcitability phenotypes in human neurons and zebrafish brains in a subset of ASD/NDD genes ( ASH1L , SCN2A, ANK2, CACNA1G, SHANK3) . Two genes, ASH1L and SCN2A , show comprehensive estradiol rescue of differential gene expression and network bursting activity in human neurons as well as sleep-wake and visual-startle phenotypes in larval zebrafish mutants. Moreover, estradiol rescues seizures and regional increases in brain activity in SCN2A larval zebrafish mutants. Altogether, we describe novel roles of estradiol in modulating network hyperexcitability in the context of loss of function mutations of select ASD/NDD genes.
- 6 October 2025
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 64 (10) , S156
RESEARCH INSTITUTE: EMERGING THERAPEUTICS AND THE PROMISE OF PRECISION MEDICINE FOR NEURODEVELOPMENTAL DISORDERS
- 6 October 2025
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 64 (10) , S156
RESEARCH INSTITUTE: EMERGING THERAPEUTICS AND THE PROMISE OF PRECISION MEDICINE FOR NEURODEVELOPMENTAL DISORDERS
- 6 October 2025
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 64 (10) , S349
FROM THE BENCH TO BEDSIDE: UNDERSTANDING THE PATHOGENESIS OF ASD
- 6 October 2025
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 64 (10) , S349
FROM THE BENCH TO BEDSIDE: UNDERSTANDING THE PATHOGENESIS OF ASD
- 13 August 2025
- Published by Wiley in Annals of Neurology
- Vol. 98 (6) , 1163-1177
Molecular and Genetic Mechanisms in Autism Spectrum Disorder
Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders characterized by deficits in social communication and interaction and the presence of repetitive and restricted behaviors. ASDs are clinically and genetically heterogeneous with hundreds of genes identified through large‐scale whole exome and genome sequencing studies contributing to risk. Recent studies are beginning to illuminate shared mechanisms across ASD‐associated genes at the molecular, cellular, circuit, and behavioral levels, identifying neurogenesis and excitatory‐inhibitory neuron development as points of biological convergence. These functional analyses of ASD genes provide substantial promise for gaining a deeper understanding of ASD pathophysiology and elucidating novel therapeutic targets. ANN NEUROL 2025;98:1163–1177
- 13 August 2025
- Published by Wiley in Annals of Neurology
- Vol. 98 (6) , 1163-1177
Molecular and Genetic Mechanisms in Autism Spectrum Disorder
Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders characterized by deficits in social communication and interaction and the presence of repetitive and restricted behaviors. ASDs are clinically and genetically heterogeneous with hundreds of genes identified through large‐scale whole exome and genome sequencing studies contributing to risk. Recent studies are beginning to illuminate shared mechanisms across ASD‐associated genes at the molecular, cellular, circuit, and behavioral levels, identifying neurogenesis and excitatory‐inhibitory neuron development as points of biological convergence. These functional analyses of ASD genes provide substantial promise for gaining a deeper understanding of ASD pathophysiology and elucidating novel therapeutic targets. ANN NEUROL 2025;98:1163–1177